** Shares of cancer diagnostic maker Grail GRAL.O falls 3% to $37.16
** Ningi Research says it is short on Grail's position citing co's "overly ambitious approach" to cancer screening that has created "insurmountable regulatory roadblocks"
** "We believe Grail's cancer detection test is backed by data that is just enough to create investor hype, but far too weak to convince experts, regulators, or insurers of its clinical utility," says Ningi in its report
** Ningi says co's actual sales have "massively underperformed projections"
** GRAL stock up more than double YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。